Utilize este identificador para referenciar este registo: http://hdl.handle.net/1822/57888

TítuloSafinamide: a new hope for Parkinson's disease?
Autor(es)Teixeira, Fábio Gabriel Rodrigues
Gago, Miguel F.
Marques, Paulo César Gonçalves
Moreira, Pedro Miguel Silva
Magalhães, Ricardo José Silva
Sousa, Nuno
Salgado, A. J.
Antiparkinson Agents
Neuroprotective Agents
Parkinson Disease
RevistaDrug Discovery Today
Resumo(s)The loss of dopaminergic neurons (DAn) and reduced dopamine (DA) production underlies the reasoning behind the gold standard treatment for Parkinson's disease (PD) using levodopa (L-DOPA). Recently licensed by the European Medicine Agency (EMA) and US Food and Drug Administration (FDA), safinamide [a monoamine oxidase B (MOA-B) inhibitor] is an alternative to L-DOPA; as we discuss here, it enhances dopaminergic transmission with decreased secondary effects compared with L-DOPA. In addition, nondopaminergic actions (neuroprotective effects) have been reported, with safinamide inhibiting glutamate release and sodium/calcium channels, reducing the excitotoxic input to dopaminergic neuronal death. Effects of safinamide have been correlated with the amelioration of non-motor symptoms (NMS), although these remain under discussion. Overall, safinamide can be considered to have potential antidyskinetic and neuroprotective effects and future trials and/or studies should be performed to provide further evidence for its potential as an anti-PD drug.
Arbitragem científicayes
AcessoembargoedAccess (1 Year)
Aparece nas coleções:ICVS - Artigos em Revistas Internacionais com Referee

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
Teixeira FG. Safinamide- a new hope for Parkinson’s disease_.pdf1,03 MBAdobe PDFVer/Abrir  Solicitar cópia ao autor!

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu Currículo DeGóis